NIH

AI-designed serotonin tracker could help develop neurology drugs
AI-designed serotonin tracker could help develop neurology drugs
Pharmaforum
NIH
serotonin
neurology
artificial intelligence
Flag link:
NIH Is Planning A Study To Find Out What’s Causing Allergic Reactions To Pfizer’s Covid-19 Vaccine
NIH Is Planning A Study To Find Out What’s Causing Allergic Reactions To Pfizer’s Covid-19 Vaccine
Forbes
NIH
CDC
allergic reaction
anaphylaxis
vaccines
Pfizer
BioNTech
COVID-19
Flag link:
GlaxoSmithKline, Vir look to succeed where Lilly failed with NIH antibody study in hospitalized Covid-19 patients
GlaxoSmithKline, Vir look to succeed where Lilly failed with NIH antibody study in hospitalized Covid-19 patients
Endpoints
GSK
Vir Biotechnology
Eli Lilly
antibodies
NIH
COVID-19
clinical trials
Flag link:
Study: ECMO ‘significantly’ improves heart attack patients’ survival
Study: ECMO ‘significantly’ improves heart attack patients’ survival
Mass Device
NIH
ECMO
heart attacks
devices
Flag link:
Coronavirus vaccine trial leader Larry Corey on the tough FDA, policy decisions to come
Coronavirus vaccine trial leader Larry Corey on the tough FDA, policy decisions to come
BioPharma Dive
vaccines
FDA
NIH
Moderna Therapeutics
COVID-19
Flag link:
Eli Lilly and Gilead’s combination cuts COVID-19 recovery time
Eli Lilly and Gilead’s combination cuts COVID-19 recovery time
Pharmaforum
Eli Lilly
olumiant
baricitinib
Gilead Sciences
Veklury
remdesivir
COVID-19
clinical trials
NIH
Flag link:
AstraZeneca's COVID-19 vaccine adverse event has NIH 'very concerned'
AstraZeneca's COVID-19 vaccine adverse event has NIH 'very concerned'
Fierce Biotech
NIH
vaccines
clinical trials
COVID-19
AstraZeneca
AZD1222
Flag link:
NIH advisors say data doesn't support plasma use for COVID-19
NIH advisors say data doesn't support plasma use for COVID-19
BioPharma Dive
NIH
convalescent plasma
COVID-19
FDA
Flag link:
Alzheon returns, with a $47 million NIH grant and one last shot at a pivotal PhIII Alzheimer’s success
Alzheon returns, with a $47 million NIH grant and one last shot at a pivotal PhIII Alzheimer’s success
Endpoints
Alzheon
NIH
grants
Alzheimer's disease
ALZ-801
Flag link:
Gilead's COVID med remdesivir is scarce and costly, AGs say, urging feds to sidestep its patents
Gilead's COVID med remdesivir is scarce and costly, AGs say, urging feds to sidestep its patents
Fierce Pharma
Gilead Sciences
remdesivir
COVID-19
FDA
NIH
HHS
drug pricing
Flag link:
Seven plucky diagnostics companies win a $249M round of contracts after surviving NIH's Covid-19 'Shark Tank' competition
Seven plucky diagnostics companies win a $249M round of contracts after surviving NIH's Covid-19 'Shark Tank' competition
Endpoints
diagnostics
COVID-19
NIH
RADx
pandemic
Quidel
Mesa Biotech
Talis Biomedical
Ginkgo Bioworks
Helix OpCo
Fluidigm
Mammoth Biosciences
Flag link:
Medical researchers sign open letter calling for COVID-19 human challenge trials
Medical researchers sign open letter calling for COVID-19 human challenge trials
Beckers Hospital Review
NIH
pandemic
vaccines
COVID-19
clinical trials
Flag link:
NIH rolls out COVID-19 clinical trials network: 5 things to know
NIH rolls out COVID-19 clinical trials network: 5 things to know
Beckers Hospital Review
clinical trials
NIH
COVID-19
pandemic
COVID-19 Prevention Trials Network
Flag link:
Gilead Covid-19 drug remdesivir benefited from $6.5B in NIH-funded basic research, study finds
Gilead Covid-19 drug remdesivir benefited from $6.5B in NIH-funded basic research, study finds
MedCity News
Gilead Sciences
remdesivir
NIH
COVID-19
Flag link:
Former Sanofi research exec Zerhouni favorite for COVID-19 czar: report
Former Sanofi research exec Zerhouni favorite for COVID-19 czar: report
Fierce Biotech
COVID-19
vaccines
NIH
Sanofi
Elias Zerhouni
Flag link:
Inside the NIH’s controversial decision to stop its big remdesivir study
Inside the NIH’s controversial decision to stop its big remdesivir study
Stat
Gilead Sciences
remdesivir
NIH
clinical trials
COVID-19
pandemic
Flag link:
After NIH trial, EMA begins rolling review for remdesivir, setting up potential authorizations in US and Europe
After NIH trial, EMA begins rolling review for remdesivir, setting up potential authorizations in US and Europe
Endpoints
Gilead Sciences
remdesivir
COVID-19
EMA
NIH
FDA
Europe
Flag link:
A COVID-19 treatment inspired by llamas
A COVID-19 treatment inspired by llamas
Fierce Biotech
COVID-19
antibodies
drug development
nanobodies
NIH
animal research
Flag link:
BARDA director abruptly departs agency tasked with leading nation's vaccine development
BARDA director abruptly departs agency tasked with leading nation's vaccine development
BioPharma Dive
vaccines
COVID-19
BARDA
NIH
Flag link:
NIH partners with 16 drug companies in hopes of accelerating Covid-19 treatments and vaccines
NIH partners with 16 drug companies in hopes of accelerating Covid-19 treatments and vaccines
Stat
NIH
vaccines
drug development
pandemic
COVID-19
R&D
Flag link:

Pages